Skip to main content

Table 1 Baseline characteristics of VS-HTG and comparison cohorts

From: Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study

 

VS-HTG Cohort

N = 2869

Comparison Cohort

N = 6,742,506

Standardized differences

P-value

Age at index date, years

 Mean (SD)

47.28 ± 10.87

51.74 ± 16.21

0.32

< 0.001

 Median (IQR)

47.0 (40.00–54.00)

52.0 (40.00–63.00)

0.35

< 0.001

 18–30 yrs

174 (6.1%)

744,062 (11.0%)

0.18

< 0.001

 31–45 yrs

1078 (37.6%)

1,642,193 (24.4%)

0.29

 46–65 yrs

1481 (51.6%)

2,963,456 (44.0%)

0.15

 66+ yrs

136 (4.7%)

1,392,795 (20.7%)

0.49

Sex, female

630 (22.0%)

3,667,595 (54.4%)

0.71

< 0.001

Income quintilea

 1 - lowest

690 (24.1%)

1,231,411 (18.3%)

0.14

< 0.001

 2

649 (22.6%)

1,323,360 (19.6%)

0.07

 3

635 (22.1%)

1,371,761 (20.3%)

0.04

 4

493 (17.2%)

1,432,535 (21.2%)

0.1

 5 - highest

402 (14.0%)

1,383,439 (20.5%)

0.17

Rostered to a GP

2346 (81.8%)

5,619,709 (83.3%)

0.04

0.023

Comorbidities

 Diabetes (Type 1 and Type 2)

1262 (44.0%)

940,151 (13.9%)

0.70

< 0.001

 Hypertension

1244 (43.4%)

2,232,885 (33.1%)

0.21

< 0.001

 Coronary artery disease (excluding angina)

339 (11.8%)

600,499 (8.9%)

0.10

< 0.001

 Cardiovascular disease

87 (3.0%)

218,670 (3.2%)

0.01

0.524

 Peripheral vascular disease

18 (0.6%)

21,539 (0.3%)

0.04

0.003

 Chronic liver disease

226 (7.9%)

230,046 (3.4%)

0.19

< 0.001

 Alcohol

66 (2.3%)

24,957 (0.4%)

0.17

< 0.001

 Obesity

53 (1.8%)

38,645 (0.6%)

0.12

< 0.001

 Hypothyroidism

15 (0.5%)

24,618 (0.4%)

0.02

0.161

 Multiple myeloma

0

1060 (0.0%)

0.02

0.502

 Nephrotic syndrome

29 (1.0%)

14,392 (0.2%)

0.10

< 0.001

 Chronic kidney disease

199 (6.9%)

209,348 (3.1%)

0.18

< 0.001

 Acute Pancreatitis

177 (6.2%)

19,602 (0.3%)

0.34

< 0.001

 Gallstone disease

212 (7.4%)

114,035 (1.7%)

0.28

< 0.001

 Current pregnancy in women

47 (1.6%)

385,120 (5.7%)

0.22

< 0.001

Charlson comorbidity index

 Mean (SD)

0.92 ± 1.38

0.44 ± 1.05

0.39

< 0.001

 Median (IQR)

0.00 (0.00–1.00)

0.00 (0.00–0.00)

0.52

< 0.001

 0

2241 (78.1%)

6,104,946 (90.5%)

0.35

< 0.001

 1

331 (11.5%)

302,652 (4.5%)

0.26

 2

142 (4.9%)

193,468 (2.9%)

0.11

 3+

155 (5.4%)

141,440 (2.1%)

0.17

Health care utilization

 Primary care (FP/GP) visits

  Mean (SD)

6.87 ± 8.85

5.24 ± 6.45

0.21

< 0.001

  Median (IQR)

5.00 (2.00–8.00)

4.00 (2.00–7.00)

0.21

< 0.001

 Endocrinologist visits

  Mean (SD)

0.23 ± 0.93

0.06 ± 0.48

0.22

< 0.001

 Internal medicine visits

  Mean (SD)

1.03 ± 2.90

0.62 ± 2.36

0.15

< 0.001

Laboratory measurements

 HbA1c

1083 (37.7%)

929,242 (13.8%)

0.57

< 0.001

 HbA1c > 8.5%

397 (13.8%)

100,258 (1.5%)

0.48

< 0.001

  Mean (SD)

7.88 ± 2.29

6.63 ± 1.37

0.67

< 0.001

  Median (IQR)

7.30 (6.00–9.40)

6.20 (5.80–7.10)

0.53

< 0.001

 LDL cholesterol

485 (16.9%)

955,143 (14.2%)

0.08

< 0.001

  Mean (SD) mmol/L

2.52 ± 1.49

2.71 ± 1.02

0.15

< 0.001

  Median (IQR) mmol/L

2.31 (1.49–3.26)

2.58 (1.93–3.38)

0.25

< 0.001

 HDL cholesterol

1202 (41.9%)

986,111 (14.6%)

0.64

< 0.001

  Mean (SD) mmol/L

0.97 ± 0.38

1.27 ± 0.38

0.79

< 0.001

  Median (IQR) mmol/L

0.91 (0.76–1.11)

1.21 (1.00–1.47)

0.93

< 0.001

non-HDL cholesterol

327 (11.4%)

18,595 (0.3%)

0.49

< 0.001

  Mean (SD) mmol/L

5.14 ± 2.27

4.58 ± 1.38

0.30

< 0.001

  Median (IQR) mmol/L

4.68 (3.75–5.98)

4.52 (3.64–5.40)

0.17

0.001

 Total cholesterol

1206 (42.0%)

994,409 (14.7%)

0.63

< 0.001

  Mean (SD) mmol/L

6.41 ± 2.75

4.78 ± 1.25

0.76

< 0.001

  Median (IQR) mmol/L

5.79 (4.71–7.33)

4.66 (3.85–5.57)

0.74

< 0.001

 ALT

1282 (44.7%)

1,384,012 (20.5%)

0.53

< 0.001

  Mean (SD) U/L

40.99 ± 39.83

27.36 ± 29.50

0.39

< 0.001

  Median (IQR)

31.00 (21.00–46.00)

22.00 (17.00–31.00)

0.58

< 0.001

 Corrected calcium

210 (7.3%)

166,005 (2.5%)

0.23

< 0.001

  Mean (SD) mmol/L

2.30 ± 0.15

2.31 ± 0.11

0.12

0.045

  Median (IQR) mmol/L

2.29 (2.23–2.37)

2.31 (2.24–2.37)

0.10

0.127

  1. Standardized difference > 10% are considered statistically significant; < 1% of income quintiles were missing and were re-coded as ‘3’; Small cells (< 6) are suppressed as per ICES privacy policy; Comorbidities were obtained in the 5 years prior to the index date; Health care utilization measures were obtained in the 1 year prior to index date; Health care utilization measures were obtained in the 1 year prior to index date; Laboratory measurements were obtained in the 1 year prior to index prescription date; Evidence of pregnancy in women was obtained in the 1 year prior and within 9 month after to index date. Please refer to supplementary Table 1 for further information on coded data included for each variable. aMissing income (< 1%) was recoded as ‘3’. Missing Charlson (~ 50%) was due to patients having no hospitalizations for relevant comorbidities found during the 5 year lookback period; they were recoded as ‘0’; ^P-value for variable as a whole
  2. Abbreviations: VS-HTG very severe hypertriglyceridemia (TG > 20 mmol/L), yrs. years, SD Standard deviation, IQR Interquartile range, GP General Practitioner, HTN hypertension, CAD coronary artery disease, PVD peripheral vascular disease, CVD cerebrovascular disease, CKD chronic kidney disease, FP family practitioner, HbA1c hemoglobin A1c, LDL low-density lipoprotein, HDL high density lipoprotein, ALT alanine aminotransferase
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X